Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MyndRenew is a medical technology company focused on developing and commercializing neuro-rehabilitation solutions for individuals with upper limb paralysis. The company's flagship product, MyndMove, is a non-invasive functional electrical stimulation (FES) therapy designed to help patients regain voluntary motor function following a stroke or spinal cord injury. By utilizing a proprietary software-controlled device to deliver multi-channel stimulation, MyndRenew aims to promote neuroplasticity and permanent functional recovery. The therapy is currently available through specialized clinics and is supported by clinical evidence demonstrating significant improvements in reaching and grasping capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MyndRenew.